期刊文献+

siRNA沉默PELP1基因对结肠癌Lovo恶性生物学行为影响的实验研究 被引量:2

Influence of PELP1 downregulation by siRNA in colon cancer cell line Lovo
下载PDF
导出
摘要 目的:明确雌激素受体共调节因子脯氨酸,谷氨酸,亮氨酸富集蛋白1(PELP1)在结肠癌Lovo中的作用及其机制。方法:使用siRNA沉默结肠癌Lovo中的PELP1基因,并观察沉默前后结肠癌Lovo恶性生物学行为的变化。结果:PELP1的沉默效率可达80%,沉默后Lovo的增殖能力、克隆形成能力、迁移和侵袭能力均下降。结论:在结肠癌Lovo中沉默PELP1可以降低Lovo的恶性程度,提示PELP1在Lovo中起癌基因的作用。 Objeetive: To identify the role of PELP1 in colon cancer cell line Lovo and its mecha- nism. Methods: The expression of PELP1 was silenced by siRNA in Lovo and the change of Lovo re- lated to malignant behaviour was watched. Results: The silent efficience of siRNA for PELP1 reached 80%.After PELP1 being silent,proliferation ability, colony formation ability, migratory and invasive ability of Lovo decreased. Conclusion: PELP1 acts as an oncogene in colon cancer cell line Lovo.
出处 《中国现代普通外科进展》 CAS 2013年第4期253-256,共4页 Chinese Journal of Current Advances in General Surgery
基金 湖北省教育厅B类指导性项目(B20112806) 湖北科技学院博士启动基金(BK0908)
关键词 结肠肿瘤·脯氨酸 谷氨酸 亮氨酸富集蛋白1·siRNA Colon neoplasms. Proline, -glutamic acid, -leucine rich protein 1 .siRNA
  • 相关文献

参考文献15

  • 1Grivas PD, Tzelepi V, Sotiropoulou-Bonikou G, et al. Expression of ERα. ERβ and co-regulator PELPI/MNAR in colorectal cancer: Prognostic signi?cance and clinicopalhologic correlations [J]. Cell Oncol. 2009.31 ( 3 ) :235-247.
  • 2Rajhans R, Vadlamudi RK. Comprehensive analysis of recent bio- chemical and l,iologic findings regarding a newly discovered pro- tein-PELPI/MNAR[J]. Clin Exp Metastasis, 2006,23(1):1-7.
  • 3Wong C-W, McNally C, Nickbarg E, et al. Estrogen receptor-inter- acting protein that modulates its nongenomic activity-crosstalk with Src Erk phosphorylation cascade[J]. Proc Nail Acad Sci USA, 2002, 99(23):14783-14788.
  • 4Vadlammli RK, Wang RA, Mazumdar A, el al. Molecular cloning and characlerization of PELPI. a novel human coregulator of eslro- gen receplor et[J]. J Biol Chem. 2001.276(41 ):38272-38279.
  • 5Vadtamudi RK, Bagheri-Yarmand R, Yang Z, et al. Dynein light cilain 1, a p21-aclivated kinase 1-interacting subslrate, promoles cancerous phenotypes[J]. Cancer Cell, 2004.5 (6):575-585.
  • 6Vadlamudi RK. Balascnthil S, Broaddus RR, et al. Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine- rich pnotein-l/modulator of nongenomic activity of estrogen receptor in human endomelrial tumors [J]. J Clin Endocrinol Metab, 2004,89 ( 12):6130-6138.
  • 7Dimple C, Nair SS, Rajhans R, et al. Role of PELPI/MNAR signal- ing in ovarian tumorigenesis [J]. Cancer Res, 2008,68 (12):4902- 4909.
  • 8Nair SS, Guo Z, Mueller JM, et al. PELP1/MNAR enhances andro- gen receptor functions through LlM-only coactivalor FHL2 [J]. MolEndocrinol, 2007,21 (3):613-624.
  • 9Dimple C. Nair SS, Rajhans R, et al. Role of PELPI/MNAR signal- ing in ovarian tumorigenesis [J]. Cancer Res, 2008,68 (12):4902- 4909.
  • 10Rajhans R, Nair S, Holden AH, et al. Oncogenic Potential of the Nuclear Receptor Coregulator Proline-,Glutamic Acid , Leucine- Rich Protein 1/Modulator of the Nongenomic Actions of the Estro- gen Receptor[J]. Cancer Res, 2007,67( 11 ):5505-5512.

二级参考文献8

  • 1Rory K,Dara O,Aisling M,et al.Oestrogen and the colon:potential mechanisms for cancer prevention[J].Lancet Oncol,2008,9(4):385-391.
  • 2Johan H,Jan-Ake G.Estrogen receptors in eolorectal cancer:.Goalkeepers,Strikers,or Bystanders[J].Cancer Prev Res,2010,3(8):897-899.
  • 3Hess R,BuLun S.Estrogen production and action[J].J Am Acad Dermatol,2001,9(4):116-124.
  • 4Antonio M,Marcello M.Nuclear alternate estrogen receptor GPR30mediates 17β-Estradiol -induced gane expression and migration in breast cancer-associated fibroblasts[J].Cancer Res,2010,7(15):6036-6042.
  • 5Kostis P,Kostas T,Annie J,et al.Subsite-speeific differences of estrogen receptor beta expression in the normal colonic epithelium:implications for carcinogenesis and colorectal cancer epidemiology[J].Eur J Gastroenterol Hepatol,2010,22(8):614-619.
  • 6张涛 崔彦.雌激素受体β及其与肿瘤关系的研究进展.中国实验诊断学,2010,14(12):1646-1649.
  • 7Emily MF,Josefa A,Magaret AS,et al.Novel action of estrogen to promote proliferation:integration of cytoplasmic and nuclear pathways[J].Steroids,2009,74(13):622-627.
  • 8Yu X,Filardo E.Shaikh A.The membrane estrogen receptor GPR30 mediates cadmium-induced proliferation of breast cancer cells[J].Toxicol Appl Pharmacol,2010,2(11):26-34.

同被引文献27

  • 1王斌,宋燕.骨桥蛋白在结肠癌组织中的表达及血清水平检测[J].吉林大学学报(医学版),2007,33(2):324-326. 被引量:4
  • 2Trzpis M, McLaughlin PM, de Leij LM, et al. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol, 2007,171 (2):386-395.
  • 3Chaves-Perez A, Mack B, Maetzel D, et al. EpCAM regulates cell cycle progression via control of eyelin DI expression . Oncogene. 2013,32(5):641-650.
  • 4Went P, Vasei M, Bubendorf L, et al. Frequent high-level expres- sion of the immunotherapeutic target EpCAM in colon, stomach, prostate and lung cancers[J]. Br J Cancer, 2006,94( 1 ):128-135.
  • 5Spizzo G, Fong D, Wurm M, et al. EpCAM expression in primary turnout tissues and metastases:an immunohistochemical analysis[J]. J Clin Pathol, 2011,64(5):415-420.
  • 6Dykxhoom D M, Chowdhury D, Lieberman J. RNA interference and cancer: endogenous pathways and therapeutic approaches [M]//Pro- grammed Cell Death in Cancer Progression and Therapy. Springer Netherlands, 2007:299-329.
  • 7Dylla SJ, Beviglia L, Park IK, et al. Colorectal cancer stem cells are enriched in xenogeneie tumom following chemotherapy [J]. PLoS One, 2008,3 (6):e2468.
  • 8Osta WA, Chen Y, Mikhitarian K, et al. EPCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy[J]. Cancer Res, 2004,64(16):5818-5824.
  • 9Du W, Ji H, Cao S, et al. EpCAM: a potential antimetastatic target for gastric cancer[J], Dig Dis Sci, 2010,55(8):2165-2171.
  • 10Eichelberg C, Churl FK, Bedke J, et al. Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma[J]. Int J Cancer, 2013,132(12):2948-2955.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部